Hepion Total Current Assets vs Non Current Assets Total Analysis
HEPA Stock | USD 1.47 0.11 8.09% |
Hepion Pharmaceuticals financial indicator trend analysis is much more than just examining Hepion Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hepion Pharmaceuticals is a good investment. Please check the relationship between Hepion Pharmaceuticals Total Current Assets and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
Total Current Assets vs Non Current Assets Total
Total Current Assets vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hepion Pharmaceuticals Total Current Assets account and Non Current Assets Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Hepion Pharmaceuticals' Total Current Assets and Non Current Assets Total is 0.53. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of Hepion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Hepion Pharmaceuticals' Total Current Assets and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Hepion Pharmaceuticals are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Total Current Assets i.e., Hepion Pharmaceuticals' Total Current Assets and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.53 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from Hepion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' Enterprise Value Over EBITDA is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to 9,137.
Hepion Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Hepion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hepion Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Other Current Liab | 851.2K | 659.6K | 3.0M | 366.2K | 386K | 366.7K | |
Total Current Liabilities | 1.6M | 4.7M | 8.2M | 7.9M | 5.3M | 3.8M | |
Total Stockholder Equity | 15.6M | 40.5M | 93.0M | 49.9M | 7.3M | 6.9M | |
Net Debt | (13.1M) | (40.0M) | (91.0M) | (51.1M) | (14.6M) | (15.3M) | |
Retained Earnings | (83.8M) | (104.1M) | (133.5M) | (175.7M) | (224.6M) | (213.4M) | |
Accounts Payable | 491.6K | 3.7M | 2.4M | 2.7M | 2.3M | 2.0M | |
Cash | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 22.3M | |
Cash And Short Term Investments | 13.9M | 40.7M | 91.3M | 51.2M | 14.8M | 24.2M | |
Common Stock Total Equity | 1.7K | 375.0 | 3.2K | 7.6K | 8.8K | 9.2K | |
Common Stock Shares Outstanding | 102.2K | 483.9K | 3.5M | 3.8M | 4.0M | 4.2M | |
Liabilities And Stockholders Equity | 20.6M | 48.6M | 103.6M | 60.2M | 18.1M | 27.5M | |
Non Current Liabilities Total | 3.4M | 3.5M | 2.4M | 2.5M | 5.5M | 4.0M | |
Other Stockholder Equity | 97.7M | 142.9M | 224.8M | 223.9M | 230.3M | 241.8M | |
Total Liab | 5.0M | 8.1M | 10.6M | 10.4M | 10.8M | 7.7M | |
Total Current Assets | 14.4M | 42.6M | 97.5M | 56.5M | 17.5M | 24.0M | |
Common Stock | 25.0 | 375.0 | 3.2K | 7.6K | 482.0 | 457.9 | |
Non Currrent Assets Other | 306.9K | 285.1K | 583.3K | 426.2K | 301.7K | 222.4K | |
Property Plant And Equipment Gross | 855.1K | 108.4K | 696.7K | 439.2K | 621.8K | 652.9K | |
Property Plant And Equipment Net | 855.1K | 664.9K | 456.5K | 132.2K | 242.4K | 289.1K | |
Non Current Assets Total | 6.2M | 6.0M | 6.1M | 3.7M | 606.6K | 576.2K | |
Other Assets | 3.3M | 4.0M | 583.3K | 426.2K | 490.1K | 465.6K | |
Capital Surpluse | 76.7M | 97.7M | 142.9M | 223.9M | 257.5M | 270.4M | |
Other Current Assets | 465.7K | 1.9M | 6.1M | 5.3M | 2.7M | 2.0M | |
Property Plant Equipment | 855.1K | 664.9K | 456.5K | 81.6K | 93.9K | 89.2K | |
Short Long Term Debt Total | 807.4K | 752.2K | 317.0K | 53.6K | 209.0K | 360.0K | |
Other Liab | 2.5M | 3.0M | 2.3M | 2.5M | 2.3M | 3.2M | |
Net Tangible Assets | 12.6M | 36.9M | 86.2M | 45.0M | 51.7M | 54.3M | |
Non Current Liabilities Other | 2.4M | 2.6M | 1.9M | 2.1M | 1.6M | 2.0M | |
Net Invested Capital | 14.5M | 39.0M | 91.3M | 48.2M | 5.6M | 5.3M | |
Net Working Capital | 13.1M | 38.0M | 89.2M | 48.6M | 12.2M | 11.6M | |
Short Term Debt | 266.7K | 279.8K | 266.7K | 53.6K | 115.9K | 110.1K | |
Capital Stock | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Hepion Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.32) | Return On Assets (0.72) | Return On Equity (1.71) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.